American Century Companies Inc. Has $15.15 Million Stake in Illumina, Inc. $ILMN

American Century Companies Inc. decreased its stake in Illumina, Inc. (NASDAQ:ILMN) by 15.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 191,003 shares of the life sciences company’s stock after selling 35,849 shares during the quarter. American Century Companies Inc. owned approximately 0.12% of Illumina worth $15,154,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Rakuten Securities Inc. lifted its position in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after buying an additional 270 shares in the last quarter. Center for Financial Planning Inc. purchased a new stake in Illumina in the 1st quarter worth approximately $33,000. Fourth Dimension Wealth LLC purchased a new stake in Illumina in the 4th quarter worth approximately $40,000. PFS Partners LLC lifted its position in Illumina by 400.0% in the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after buying an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC lifted its position in Illumina by 123.2% in the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after buying an additional 292 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ ILMN opened at $101.80 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a market capitalization of $15.65 billion, a price-to-earnings ratio of 12.89, a P/E/G ratio of 2.29 and a beta of 1.37. The company’s fifty day moving average is $98.18 and its two-hundred day moving average is $88.64. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s quarterly revenue was down 4.8% on a year-over-year basis. During the same period last year, the business posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on ILMN shares. Evercore ISI lifted their target price on shares of Illumina from $116.00 to $128.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Guggenheim dropped their target price on shares of Illumina from $122.00 to $114.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group lifted their target price on shares of Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a report on Friday, August 1st. Wall Street Zen downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Daiwa Capital Markets downgraded shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price on the stock. in a report on Tuesday, August 12th. Seven investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $124.58.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.